Association between variants in TCF7L2, CTRB1/2, and GLP-1R genes and response to therapy with glucagon-like peptide-1 receptor agonists

References

• Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102
   PubMed Web of Science ®Google Scholar
• Karras SN, Rapti E, Koufakis T, et al. Pharmacogenetics of glucagon-like peptide-1 agonists for the treatment of type 2 diabetes mellitus. Curr Clin Pharmacol. 2017;12(4):202–209.
   PubMedGoogle Scholar
• Kyriakidou A, Koufakis T, Goulis DG, et al. Pharmacogenetics of the glucagon-like peptide-1 receptor agonist liraglutide: a step towards personalized type 2 diabetes management. Curr Pharm Des. 2021;27(8):1025–1034. doi: 10.2174/1381612826666201203145654
   PubMed Web of Science ®Google Scholar
• Jakhar K, Vaishnavi S, Kaur P, et al. Pharmacogenomics of GLP-1 receptor agonists: Focus on pharmacological profile. Eur J Pharmacol. 2022;936:175356. doi: 10.1016/j.ejphar.2022.175356
   PubMed Web of Science ®Google Scholar
• Dawed AY, Mari A, Brown A, et al. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes Endocrinol. 2023;11(1):33–41. doi: 10.1016/S2213-8587(22)00340-0
   PubMed Web of Science ®Google Scholar
• Shu L, Matveyenko AV, Kerr-Conte J, et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum Mol Genet. 2009;18(13):2388–2399. doi: 10.1093/hmg/ddp178
   PubMed Web of Science ®Google Scholar
• Del Bosque-Plata L, Martínez-Martínez E, Espinoza-Camacho MÁ, et al. The role of TCF7L2 in type 2 diabetes. Diabetes. 2021;70(6):1220.
   PubMed Web of Science ®Google Scholar
• Tong Y, Lin Y, Zhang Y, et al. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large Human Genome Epidemiology (HuGE) review and meta-analysis. BMC Med Genet. 2009;10(1):15.
   PubMedGoogle Scholar
• Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes. 2007;56(8):2178–2182. doi: 10.2337/db07-0440
   PubMed Web of Science ®Google Scholar
• T’Hart LM, Fritsche A, Nijpels G, et al. The CTRB1/2 locus affects diabetes susceptibility and treatment via the incretin pathway. Diabetes. 2013;62(9):3275–3281. doi: 10.2337/db13-0227
   PubMed Web of Science ®Google Scholar
• Tokuyama Y, Matsui K, Egashira T, et al. Five missense mutations in glucagon-like peptide 1 receptor gene in Japanese population. Diabet Res Clin Pract. 2004;66(1):63–69. doi: 10.1016/j.diabres.2004.02.004
   PubMed Web of Science ®Google Scholar
• Beinborn M, Worrall CI, McBride EW, et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness. Regul Pept. 2005;130(1–2):1–6. doi: 10.1016/j.regpep.2005.05.001
   PubMedGoogle Scholar
• Shalaby SM, Zidan HE, Shokry A, et al. Association of incretin receptors genetic polymorphisms with type 2 diabetes mellitus in Egyptian patients. J Gene Med. 2017;19(9–10). doi: 10.1002/jgm.2973
   PubMed Web of Science ®Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl 1):S19–40.
   PubMedGoogle Scholar
• Kyriakidou A, Kyriazou AV, Koufakis T, et al. Clinical and genetic predictors of glycemic control and weight loss response to liraglutide in patients with type 2 diabetes. J Pers Med. 2022;12(3):424. doi: 10.3390/jpm12030424
   PubMed Web of Science ®Google Scholar
• Recommendations | Type 2 diabetes in adults: management | Guidance | NICE. [cited 2023 Oct 2]. Available from https://www.nice.org.uk/guidance/ng28/chapter/Recommendations#blood-glucose-management-2
   Google Scholar
• ElSayed NA, Aleppo G, Aroda VR, et al. 6. Glycemic targets: standards of care in diabetes—2023. Diabetes Care. 2023;46(Suppl Supplement_1):S97–110.
   PubMedGoogle Scholar
• Turner R Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–853.
   PubMed Web of Science ®Google Scholar
• Turner R Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–865.
   PubMed Web of Science ®Google Scholar
• Song SO, Kim KJ, Lee BW, et al. Tolerability, effectiveness and predictive parameters for the therapeutic usefulness of exenatide in obese, Korean patients with type 2 diabetes. J Diabetes Investig. 2014;5(5):554–562. doi: 10.1111/jdi.12184
   PubMed Web of Science ®Google Scholar
• Deng H, Lin S, Yang X, et al. Effect of baseline body mass index on glycemic control and weight change with exenatide monotherapy in Chinese drug-naïve type 2 diabetic patients. J Diabetes. 2019;11(7):509–518. doi: 10.1111/1753-0407.12883
   PubMed Web of Science ®Google Scholar
• Dushay J, Gao C, Gopalakrishnan GS, et al. Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes. Diabetes Care. 2012;35(1):4–11. doi: 10.2337/dc11-0931
   PubMed Web of Science ®Google Scholar
• Esposito K, Mosca C, Brancario C, et al. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin. 2011;27(8):1519–1528. doi: 10.1185/03007995.2011.590127
   PubMed Web of Science ®Google Scholar
• Ferreira MC, Da Silva MER, Fukui RT, et al. Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes. Diabetol Metab Syndr. 2019;11(1):10.
   PubMedGoogle Scholar
• Florez JC. Pharmacogenetic perturbations in humans as a tool to generate mechanistic insight. Diabetes. 2013;62(9):3019–3021. doi: 10.2337/db13-0871
   PubMed Web of Science ®Google Scholar
• Khan M, Ouyang J, Perkins K, et al. Determining predictors of early response to exenatide in patients with type 2 diabetes mellitus. J Diabetes Res. 2015;2015:162718. doi: 10.1155/2015/162718
   PubMed Web of Science ®Google Scholar
• Fujioka K, O’Neil PM, Davies M, et al. Early weight loss with Liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers. Obesity. 2016;24(11):2278–2288. doi: 10.1002/oby.21629
   PubMed Web of Science ®Google Scholar
• Rentzeperi E, Pegiou S, Koufakis T, et al. Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a Tailored Approach to diabetes and obesity care. J Pers Med. 2022;12(3):454. doi: 10.3390/jpm12030454
   PubMed Web of Science ®Google Scholar
• Richard JE, Anderberg RH, López-Ferreras L, et al. Sex and estrogens alter the action of glucagon-like peptide-1 on reward. Biol Sex Differ. 2016;7(1):6.
   PubMedGoogle Scholar
• Mosikian AA, Golikova TI, Martjanova MV, et al. Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes. Future Sci OA. 2022;8(3):FSO779. doi: 10.2144/fsoa-2021-0070
   PubMed Web of Science ®Google Scholar
• Blonde L, Chava P, Dex T, et al. Predictors of outcomes in patients with type 2 diabetes in the lixisenatide GetGoal clinical trials. Diab Obes Metab. 2017;19(2):275–283.
   PubMed Web of Science ®Google Scholar